Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403420 | 0.94 | PDK2 (0.43) | ALDH1A1PDK2ROCK2LMNAHPGD | |
| SCHEMBL200851 | 0.87 | FKBP1A (0.46) | ALDH1A1PDK2ROCK2LMNAHPGD | |
| SCHEMBL4650506 | 0.83 | PDK2 (0.39) | ALDH1A1PDK2ROCK2LMNAHSD11B1 | |
| SCHEMBL4650510 | 0.83 | PDK2 (0.39) | ALDH1A1PDK2ROCK2LMNAHSD11B1 | |
| SCHEMBL201209 | 0.83 | PDK2 (0.39) | ALDH1A1PDK2ROCK2LMNAHSD11B1 | |
| SCHEMBL13403466 | 0.83 | ALDH1A1 (0.41) | ALDH1A1PDK2LMNAHPGDSMN1; SMN2 | |
| SCHEMBL13403452 | 0.82 | HPGD (0.40) | ALDH1A1PDK2HPGDMMP2MMP9 | |
| SCHEMBL13403467 | 0.81 | KDM4E (0.37) | ALDH1A1PDK2RHOCRHOAMMP2 | |
| SCHEMBL13403459 | 0.81 | L3MBTL1 (0.42) | ALDH1A1PDK2HPGDSMN1; SMN2MMP2 | |
| SCHEMBL13403432 | 0.81 | MMP2 (0.42) | ALDH1A1PDK2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | ALDH1A1 343/4885PDK2 4421/4885ROCK2 4478/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | ALDH1A1 2309/4885PDK2 2445/4885ROCK2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.